May 15th 2024
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Nivolumab/Ipilimumab Combo Induces 12% OS Benefit in Melanoma, Updated Phase III Findings Show
April 6th 2017The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.
Read More
PD-1 and IDO Inhibitor Combo Could Change Standard of Care in Melanoma
March 24th 2017The first-in-class IDO1 inhibitor epacadostat (INCB024360), currently being investigated in combination with the PD-1 inhibitor pembrolizumab (Keytruda), could be an exciting new FDA approval for patients with stage III/IV unresectable or metastatic melanoma.
Read More
Mutational Load is Only One Piece of the Immunotherapy Puzzle
March 22nd 2017As immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will respond better to immunotherapy. Mutational load is one such biomarker that appears to have an impact on response to immunotherapy, particularly for checkpoint inhibitors.
Read More
Future Combination Strategies for BRAF-Mutant Melanoma
March 16th 2017Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for <em>BRAF</em>-mutant melanoma.
Watch
Rare Cardiotoxicity Effects Founds With Checkpoint Inhibitors in Melanoma
March 16th 2017As the oncology community adapts to using immunotherapy agents more frequently in cancer treatments, the fear over immune-related adverse events (irAEs) prevents many clinicians from fully trusting immunotherapies.
Read More
Researchers Exploring Ways to Combat Drug Resistance in Melanoma
March 14th 2017Helmut Schaider, MD, discusses why drug resistance in melanoma may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.
Read More
Early Promise Seen With Nilotinib/Trametinib in BRAF/NRAS Wild-Type Melanoma
February 8th 2017The combination of nilotinib and trametinib proved to be synergistic in <em>BRAF/NRAS</em> wild-type melanoma, according to a recent study presented at the 2016 Society for Melanoma Research Congress.
Read More
Dabrafenib/Trametinib Demonstrates Dramatic RFS Improvement in BRAF-Mutant Melanoma
February 8th 2017The combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic <em>BRAF</em>-mutant melanoma.
Read More
Encorafenib/Binimetinib a Potential New Treatment Option for BRAF-Mutant Melanoma
January 24th 2017BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib for patients with <em>BRAF</em>-mutant unresectable melanoma.
Read More
SD-101, Pembrolizumab Combo Shows Promise in Melanoma
January 24th 2017Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab have demonstrated that the combination was well-tolerated with no dose-limiting toxicities in early-stage melanoma.
Read More
Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma
January 23rd 2017Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective, but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.
Read More
Atezolizumab/Cobimetinib Combination Demonstrates High Response Rate in Advanced Melanoma
December 8th 2016The addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to the MEK inhibitor cobimetinib (Cotellic) and the BRAF inhibitor vemurafenib (Zelboraf) induced a high response rate for patients with <em>BRAF</em>-mutant unresectable melanoma.
Read More
An Overview of Clinical Trials Investigating Immunotherapy Combos, Sequencing in Melanoma
November 16th 2016Igor Puzanov, MD, professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses 2 clinical trials investigating immunotherapy combinations and sequencing in melanoma.
Watch
New BRAF/MEK Combo Highly Effective in Phase III Melanoma Study
November 15th 2016Treatment with the BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib improved median progression-free survival by 7.6 months compared with monotherapy with vemurafenib for patients with <em>BRAF</em>-mutant unresectable melanoma.
Read More
Current and Emerging Immunotherapeutic Strategies in Melanoma
November 12th 2016Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, discusses current and emerging immunotherapeutic strategies in the field of melanoma during an interview at the 34th Annual Chemotherapy Foundation Symposium<sup>TM</sup>.
Watch
Immunotherapy Success Is Paving the Way for "Colder" Tumors, Allison Says
November 1st 2016James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.
Read More
Updated Results Support Frontline Dabrafenib/Trametinib in Melanoma
November 1st 2016According to an updated survival analysis of the large randomized phase III COMBI-v trial, co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.
Read More
An Overview of a Survey Examining Lack of Access to Drugs in European Melanoma Patients
October 29th 2016Lidija Kandolf-Sekulovic, MD, PhD, associate professor of Dermatology at the Military Medical Academy in Belgrade, Serbia, discusses a recent survey that examined the lack of access to lifesaving drugs in European melanoma patients.
Watch